Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.45 |
| ▸ | CCR8 | P51685 | 2/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624537 | 0.72 | KDM4E (0.62) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1456454 | 0.72 | KDM4E (0.62) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20510086 | 0.72 | KDM4E (0.50) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1988750 | 0.72 | KDM4E (0.58) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL297366 | 0.71 | NOTUM (0.47) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5709792 | 0.70 | NOTUM (0.52) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29664837 | 0.70 | NOTUM (0.52) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1456955 | 0.70 | KDM4E (0.59) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7536764 | 0.69 | BTK (0.51) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24625410 | 0.67 | KDM4E (0.68) | LMNAKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585751-A4 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY USA INC (CA) | 2008-08-13 | — | — | EP | claimed |
| JP-2006514009-A | — | — | 2006-04-27 | — | — | JP | claimed |
| US-20060063743-A1 | Peptide deformylase activated prodrugs | BALLATORE CARLO | 2006-03-23 | — | — | US | claimed |
| EP-1585751-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | Celmed Oncology (USA), Inc. (CA) | 2005-10-19 | — | — | EP | claimed |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | NEWBIOTICS, INC. | 2004-11-25 | — | — | US | claimed |
| WO-2004043400-A2 | PEPTIDE DEFORMYLASE ACTIVATED PRODRUGS | CELMED ONCOLOGY (USA), INC. (CA) | 2004-05-27 | — | — | WO | claimed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | claimed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | claimed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0647450-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-04-12 | — | — | EP | claimed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | claimed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | claimed |
| JP-3170426-A | — | — | None | — | — | JP | disclosed |
| JP-3170427-A | — | — | None | — | — | JP | disclosed |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-08 | — | — | US | disclosed |
| EP-0595133-B1 | Prodrugs, their preparation and use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-0428103-A2 | Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428103-A2 | Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428103-A2 | Prevention of glycoprotein enveloped virus infectivity by pyridyloxazole-2-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0428106-A1 | Novel pyridyloxazole 2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063743-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | LMNA 3916/4885KDM4E 2784/4885NPC1 2823/4885 |
| US-20040236096-A1 | Peptide deformylase activated prodrugs | DNPEP, DPEP1, PEPD | LMNA 3978/4885KDM4E 2746/4885NPC1 2399/4885 |
| US-20110300147-A9 | Inhibiting tumor cell invasion, metastasis and angiogenesis | MMP9, TIMP3, MMP3 | LMNA 3944/4885KDM4E 3077/4885NPC1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.